Briefly involved in SBIR soon after the firm was founded and proceeding to PhaseII, HTD Biosystems now operates as a contract formulation development lab providing services for accelerating development of parenteral drugs, biosimilars and vaccines, using high throughput technologies. HTD's expertise is in design of experiments (DOE), protein formulation, vaccine development and lyophilization.
